share_log

Biodexa Pharmaceuticals | SC 13G/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-CVI Investments, Inc.(0%),Heights Capital Management, Inc.(0%)

Biodexa Pharmaceuticals | SC 13G/A：超過5%持股股東披露文件(修正)-CVI Investments, Inc.(0%),Heights Capital Management, Inc.(0%)

美股sec公告 ·  02/15 04:37
牛牛AI助理已提取核心訊息
Biodexa Pharmaceuticals, previously known as Midatech Pharma PLC, filed an amendment to a Schedule 13G with the Securities and Exchange Commission on December 31, 2023. The filing was made by CVI Investments, Inc., with Heights Capital Management, Inc. acting as the investment manager, both of which disclaimed beneficial ownership of the shares except for their pecuniary interest. The amendment indicates that CVI Investments, Inc. and Heights Capital Management, Inc. no longer hold more than five percent of Biodexa Pharmaceuticals' ordinary shares, which have a nominal value of £0.001 per share. The filing was completed on February 12, 2024, and includes a certification that the shares were not acquired for the purpose of changing or influencing the control of the issuer.
Biodexa Pharmaceuticals, previously known as Midatech Pharma PLC, filed an amendment to a Schedule 13G with the Securities and Exchange Commission on December 31, 2023. The filing was made by CVI Investments, Inc., with Heights Capital Management, Inc. acting as the investment manager, both of which disclaimed beneficial ownership of the shares except for their pecuniary interest. The amendment indicates that CVI Investments, Inc. and Heights Capital Management, Inc. no longer hold more than five percent of Biodexa Pharmaceuticals' ordinary shares, which have a nominal value of £0.001 per share. The filing was completed on February 12, 2024, and includes a certification that the shares were not acquired for the purpose of changing or influencing the control of the issuer.
Biodexa Pharmaceuticals（前身爲Midatech Pharma PLC）於2023年12月31日向美國證券交易委員會提交了附表13G的修正案。該文件由CVI Investments, Inc.提交，由Heights Capital Management, Inc.擔任投資經理，兩家公司均否認了除金錢權益以外的股票的實益所有權。該修正案表明，CVI Investments, Inc.和Heights Capital Management, Inc.不再持有Biodexa Pharmaceuticals普通股的5％以上，後者的名義價值爲每股0.001英鎊。該文件已於2024年2月12日完成，其中包括一份證明，收購這些股票的目的不是爲了改變或影響發行人的控制權。
Biodexa Pharmaceuticals（前身爲Midatech Pharma PLC）於2023年12月31日向美國證券交易委員會提交了附表13G的修正案。該文件由CVI Investments, Inc.提交，由Heights Capital Management, Inc.擔任投資經理，兩家公司均否認了除金錢權益以外的股票的實益所有權。該修正案表明，CVI Investments, Inc.和Heights Capital Management, Inc.不再持有Biodexa Pharmaceuticals普通股的5％以上，後者的名義價值爲每股0.001英鎊。該文件已於2024年2月12日完成，其中包括一份證明，收購這些股票的目的不是爲了改變或影響發行人的控制權。
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

譯文內容由第三人軟體翻譯。


牛牛AI助手部分由第三方人工智慧模型基於資訊內容自動產生，只对除中国内地以外的地区提供。


以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。